ST PETERSBURG, FL / ACCESSWIRE / August 10, 2019 / MMJ International Holdings, the premier medical cannabis research company, announced that it will begin preparations to ship THC and CBD from Canada. MMJ International Holdings is developing an oral drug product from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing its new product for a FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). It is asking the US Drug Enforcement Agency’s approval to ship the compounds for its clinical trials.
“As MMJ International Holdings continues to advance to its clinical trials, ThermoFisher Scientific will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of research development.. “Patients will benefit from cGMP-quality therapies in an accessible